Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
MERUS LABS Aktie jetzt für 0€ handeln |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
MPH HEALTH CARE | 18,600 | -0,53 % | Original-Research: MPH Health Care AG (von First Berlin Equity Research GmbH): Kaufen | Original-Research: MPH Health Care AG - from First Berlin Equity Research GmbH
17.06.2025 / 16:27 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
EYEPOINT PHARMACEUTICALS | 8,416 | +5,31 % | EyePoint Pharmaceuticals, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients... ► Artikel lesen | |
AMARIN | 13,700 | +0,74 % | Recordati: RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA IN EUROPE | RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE
Vazkepa® supported by strong clinical data package and expected to contribute to Specialty... ► Artikel lesen | |
SELLAS LIFE SCIENCES | 1,792 | -2,50 % | SELLAS Life Sciences wird in Russell 3000 und Russell 2000 Indizes aufgenommen | ||
MADRIGAL PHARMACEUTICALS | 259,10 | +0,86 % | Madrigal, Viking among notable gainers after Altimmune's MASH setback | ||
CATALYST PHARMACEUTICALS | 18,620 | +1,09 % | Catalyst Pharma: Viel Wachstum für wenig Geld? | Die meisten Biotech-Aktien sind vor allem eins: hochspekulativ. Catalyst Pharma beweist jedoch, dass es auch anders geht - mit realen Gewinnen und nachhaltigem Wachstum Den vollständigen Artikel lesen... ► Artikel lesen | |
ANI PHARMACEUTICALS | 56,00 | +0,90 % | ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin Gel for the Treatment of Acute Gout Flares | Purified Cortrophin Gel is the only ACTH therapy approved by the FDA for the treatment of acute gout flares Trial to be conducted by Dr. Hyon Choi at Massachusetts General Hospital and will compare... ► Artikel lesen | |
DOGECOIN CASH | - | - | Dogecoin Cash, Inc.: MEME COINS INC., a Controlled Subsidiary of DOGP, to Acquire 2 Billion DOG Tokens from Tipestry | MESQUITE, NV, June 25, 2025 (GLOBE NEWSWIRE) -- Denver, CO - MEME COINS INC., a Colorado corporation and controlled subsidiary of Dogecoin Cash Inc. (OTC: DOGP), has entered into a definitive agreement... ► Artikel lesen | |
ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2025 and Provides Conference Call Information | Northvale, New Jersey--(Newsfile Corp. - June 30, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
TITAN PHARMACEUTICALS | 0,001 | -100,00 % | Titan Pharma sammelt 600.000 US-Dollar durch Privatplatzierung mit Blue Harbour | ||
BLUM HOLDINGS | - | - | Blum Holdings Inc. Reports First Quarter 2025 Financial Results | DOWNEY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Blum Holdings, Inc. (OTCQB: BLMH) (the "Company," "Blüm," "Blüm Holdings," "we" or "us"), a California-based publicly traded holding company and cannabis... ► Artikel lesen | |
BMP PHARMA TRADING | 5,900 | 0,00 % | PTA-News: B.M.P. Pharma Trading AG: B.M.P. steigert abermals das operative Rekordjahresergebnis aus dem Jahr 2023 im Geschäftsjahr 2024 - Erhöhte Umsatzprognose und Ergebnisprognose für das Geschäftsjahr 2024/25 bestätigt | DJ PTA-News: B.M.P. Pharma Trading AG: B.M.P. steigert abermals das operative Rekordjahresergebnis aus dem Jahr 2023 im Geschäftsjahr 2024 - Erhöhte Umsatzprognose und Ergebnisprognose für das Geschäftsjahr... ► Artikel lesen | |
THERIVA BIOLOGICS | 0,438 | 0,00 % | Theriva Biologics, Inc.: Theriva Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at ASCO 2025 and Investigator Meeting to Review Topline Data from the VIRAGE Phase 2b Trial of VCN-01 in Metastatic Pancreatic Canc | - Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in a poster session at the American Society of Clinical Oncology... ► Artikel lesen | |
KAZIA THERAPEUTICS | 6,120 | 0,00 % | Kazia Therapeutics Limited: Kazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer (TNBC) | SYDNEY, June 11, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a clinical-stage biotechnology company pioneering next-generation oncology therapeutics... ► Artikel lesen | |
ALLERGY THERAPEUTICS | 0,074 | 0,00 % | Allergy Therapeutics - Allergy Therapeutics presents findings at EAACI |